Toceranib

Toceranib In Dogs & Cats: Uses, Dosage and Side Effects

Overview

• Selective protein tyrosine kinase inhibitor with particular effects on the split kinase TK family, which may also have an effect on angiogenesis.

Uses of Toceranib

• Treatment of non-resectable grade 2 or 3 (Patnaik grading scheme) recurrent cutaneous mast cell tumours.
• Phase I trials have also demonstrated some efficacy in other canine malignancies (including mammary gland carcinomas, soft tissue sarcomas, multiple myelomas, melanomas and other carcinomas).

Dose of Toceranib in Dogs and Cats

Dogs:

• All uses: 2.5–3.25 mg/kg p.o. q48h or on a Monday, Wednesday, Friday basis.

Cats:

• Limited information: 2.5 mg/kg (range 1.5–3.25 mg/kg) p.o. on a Monday, Wednesday, Friday basis (or less frequently q48h).

Side Effects of Toceranib in Dogs and Cats

• Common adverse effects of toceranib include weight loss, gastrointestinal (GI) signs such as diarrhoea, haemorrhage, anorexia, and vomiting, as well as lethargy, myelosuppression, lameness or musculoskeletal disorders, dermatitis, and pruritus.
• Toceranib may also lead to anaemia, increased ALT activity, coagulation derangements (including pulmonary thromboembolism), decreased albumin, and elevated blood pressure.
• Uncommon events associated with toceranib administration include seizures, epistaxis, circulatory shock, and death.

Contraindications of Toceranib in Dogs and Cats

Some Notes:

• Use with caution when combining with chemotherapeutic agents and drugs that have the potential to cause GI toxicity (i.e. steroids, NSAIDs) until further information is available.